- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01554020
Blood Sugar Take Care and Glucose Metabolism
Effect of Blood Sugar Take Care on Glucose Metabolism, Determinants of Metabolic Syndrome, and Quality of Life in Prediabetic Adults: A Randomized, Double-blind, Placebo-controlled Study
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
California
-
San Francisco, California, Forenede Stater, 94109
- SPRIM
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
SUBJECT INCLUSION CRITERIA: STEP 1
- Age ≥ 18 years
Subject meets American Diabetes Association criteria for diabetes testing in asymptomatic, undiagnosed individuals:
- If age ≥45 years, subject must have a body mass index ≥ 25 kg/m2 for United States and ≥ 24 kg/m2 for Indonesia
If age <45 years, subject must have a body mass index ≥ 25 kg/m2 for United States and ≥ 24 kg/m2 for Indonesia AND present with at least one of the following risk factors:
- Have a first-degree relative with diabetes
- Habitually physically inactive
- Race is African-American, Hispanic American, Native American, Asian American, or Pacific Islander
- Have delivered a baby weighing >9 lb or have been diagnosed with gestational diabetes mellitus
- Hypertensive (≥140/90)
- Known HDL cholesterol level 35 mg/dl
- Known triglyceride level ≥250 mg/dl
- On previous testing, had impaired glucose tolerance or impaired fasting glucose
- History of vascular disease
- Stable body weight (<5% change) in the last 3 months
- Agree to use contraception throughout study period, unless postmenopausal or surgically sterile (females only)
- Able to understand the nature and purpose of the study including potential risks and side effects
- Willing to consent to study participation and to comply with study requirements
SUBJECT EXCLUSION CRITERIA
- Known diabetes (type I or II)
- Recent use (within 2 weeks of screening) of any dietary supplement including vitamin and mineral complexes; herbal supplements; fish oil; fiber supplements; or any herbal ingredient/product that significantly affects glucose or lipid metabolism
- Recent use (within 4 weeks of screening) of any prescription or OTC medication that significantly affects glucose or lipid metabolism, including but not limited to, sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, DPP-4 inhibitors, systemic corticosteroids, statins, fibrates, niacin, and bile acid sequestrants
- Daily use of nonsteroidal anti-inflammatory drugs (NSAIDS); (daily baby aspirin use acceptable)
- Any comorbidity that could, in the opinion of the investigator, preclude the subject's ability to successfully and safely complete the study or that may confound study outcomes
- Anticipated changes in dietary patterns or physical activity levels during the study, including attempts at body weight reduction
- Eating disorder
- Polycystic ovary syndrome
- Known allergies to any substance in the study product
- Pregnant or breastfeeding women
- History of alcohol, drug, or medication abuse
- Participation in another study with any investigational product within 3 months of screening
- Recent (<3 months) gastrointestinal surgery or any planned surgery during the treatment period
SUBJECT INCLUSION CRITERIA: STEP 2
1. Fasting glucose between 95 and 130 mg/dl, based on portable glucometer reading
SUBJECT INCLUSION CRITERIA: STEP 3
- Impaired fasting glucose, based on the American Diabetes Association definition of fasting serum glucose between 100 and 125 mg/dl
- Impaired glucose tolerance, based on the American Diabetes Association definition of serum glucose between 140 and 199 mg/dl 2 hours after a 75 g glucose load
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Multiherb product
Herbal product
|
One 1200 mg soft gel capsule administered 3X/day for duration of study
Andre navne:
|
|
Placebo komparator: Placebo
Maltodextrin control
|
One 1200 mg soft-gel capsule administered 3X/day for duration of study
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Fastende glukose
Tidsramme: 12 uger
|
12 uger
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Uønskede hændelser
Tidsramme: 12 uger
|
12 uger
|
|
|
Blodtryk
Tidsramme: 12 uger
|
12 uger
|
|
|
Insulinfølsomhedsindeks
Tidsramme: 12 uger
|
12 uger
|
|
|
Fastende insulin
Tidsramme: 12 uger
|
12 uger
|
|
|
Homeostasis Model Assessment of Insulin Resistance
Tidsramme: 12 weeks
|
12 weeks
|
|
|
Quantitative insulin sensitivity check index
Tidsramme: 12 weeks
|
12 weeks
|
|
|
Insulin secretion/insulin resistance index
Tidsramme: 12 weeks
|
12 weeks
|
|
|
Glykosyleret hæmoglobin (HbA1c)
Tidsramme: 12 uger
|
12 uger
|
|
|
High-sensitivity C-reactive protein
Tidsramme: 12 weeks
|
12 weeks
|
|
|
High-molecular weight adiponectin
Tidsramme: 12 weeks
|
12 weeks
|
|
|
Lipids (total cholesterol, HDL, LDL, VLDL, triglycerides)
Tidsramme: 12 weeks
|
12 weeks
|
|
|
Body composition
Tidsramme: 12 weeks
|
height/weight, body mass index, waist circumference, hip circumference, waist-to-hip ratio
|
12 weeks
|
|
WHO Quality of Life Questionnaire
Tidsramme: 12 weeks
|
12 weeks
|
|
|
Comprehensive metabolic panel
Tidsramme: 12 weeks
|
12 weeks
|
|
|
Fuldstændig blodtælling
Tidsramme: 12 uger
|
12 uger
|
|
|
Gastrointestinal Symptom Rating Scale
Tidsramme: 12 weeks
|
12 weeks
|
|
|
Pulse
Tidsramme: 12 weeks
|
12 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Larry Miller, PhD, Sprim Advanced Life Sciences
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 120216-SUS-NWC-BSS-GP
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Blood Sugar Take Care
-
Sohag UniversityIkke rekrutterer endnuPrædiabetisk tilstand | Prædiabetisk tilstand (IGT)Egypten
-
Beijing GoBroad HospitalRekrutteringSystemisk sklerose | Refraktær Lupus Nephritis | Primær Sjogrens syndrom kombineret med pulmonal hypertensionKina
-
National Cancer Institute (NCI)SuspenderetTilbagevendende akut myeloid leukæmi | Tilbagevendende myelodysplastisk syndrom | Refraktær akut myeloid leukæmi | Refraktært myelodysplastisk syndrom | Myelodysplastisk syndrom med overskydende blaster | Tilbagevendende myelodysplastisk syndrom/akut myeloid leukæmi | Refraktært myelodysplastisk syndrom...Forenede Stater, Canada
-
Ohio State University Comprehensive Cancer CenterRekrutteringWHO Grade 3 Gliom | Tilbagevendende malignt gliom | WHO Grade 2 Gliom | Tilbagevendende WHO Grade 3 Gliom | Tilbagevendende WHO Grade 4 Gliom | WHO Grade 4 GliomForenede Stater
-
National Cancer Institute (NCI)RekrutteringTilbagevendende Langerhans Cell Histiocytose | Refraktær Langerhans Cell HistiocytoseForenede Stater, Australien, Canada
-
Fred Hutchinson Cancer CenterPromiCell Therapeutics, Inc.RekrutteringKastrationsresistent prostatakarcinom | Stadie IVB prostatakræft AJCC v8 | Metastatisk prostataadenokarcinomForenede Stater
-
City of Hope Medical CenterNational Cancer Institute (NCI)Rekruttering
-
Sumithira VasuNational Cancer Institute (NCI)RekrutteringTilbagevendende B Akut lymfoblastisk leukæmi | Refraktær B Akut lymfatisk leukæmi | Refraktær kronisk lymfatisk leukæmi | Tilbagevendende non-Hodgkin-lymfom | Refraktær non-Hodgkin lymfom | Tilbagevendende akut lymfatisk leukæmi | Refraktær akut lymfatisk leukæmi | Tilbagevendende højgradig B-celle lymfom og andre forholdForenede Stater
-
Ohio State University Comprehensive Cancer CenterRekrutteringRefraktær kronisk lymfatisk leukæmi | Tilbagevendende non-Hodgkin-lymfom | Refraktær non-Hodgkin lymfom | Tilbagevendende akut lymfatisk leukæmi | Refraktær akut lymfatisk leukæmi | Tilbagevendende kronisk lymfatisk leukæmi | Refraktær lymfoblastisk lymfom | Tilbagevendende transformeret kronisk lymfatisk... og andre forholdForenede Stater
-
Fred Hutchinson Cancer CenterSimcha TherapeuticsRekrutteringTilbagevendende diffust stort B-cellet lymfom | Refraktært diffust stort B-cellet lymfom | Tilbagevendende diffust stort B-cellet lymfom, ikke andet specificeret | Refraktært diffust stort B-cellet lymfom, ikke andet specificeret | Tilbagevendende grad 3b follikulært lymfom | Refraktær grad 3b... og andre forholdForenede Stater